-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Here's Why We Think Chemours (NYSE:CC) Might Deserve Your Attention Today
Here's Why We Think Chemours (NYSE:CC) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Chemours (NYSE:CC). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Chemours with the means to add long-term value to shareholders.
View our latest analysis for Chemours
Chemours' Earnings Per Share Are Growing
If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. That means EPS growth is considered a real positive by most successful long-term investors. Chemours managed to grow EPS by 17% per year, over three years. That's a pretty good rate, if the company can sustain it.
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. The music to the ears of Chemours shareholders is that EBIT margins have grown from 8.2% to 15% in the last 12 months and revenues are on an upwards trend as well. Ticking those two boxes is a good sign of growth, in our book.
You can take a look at the company's revenue and earnings growth trend, in the chart below. For finer detail, click on the image.
NYSE:CC Earnings and Revenue History September 28th 2022The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Chemours' future EPS 100% free.
Are Chemours Insiders Aligned With All Shareholders?
It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. Shareholders will be pleased by the fact that insiders own Chemours shares worth a considerable sum. To be specific, they have US$44m worth of shares. That shows significant buy-in, and may indicate conviction in the business strategy. Even though that's only about 1.2% of the company, it's enough money to indicate alignment between the leaders of the business and ordinary shareholders.
It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. A brief analysis of the CEO compensation suggests they are. The median total compensation for CEOs of companies similar in size to Chemours, with market caps between US$2.0b and US$6.4b, is around US$6.9m.
Chemours offered total compensation worth US$5.5m to its CEO in the year to December 2021. That is actually below the median for CEO's of similarly sized companies. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of a culture of integrity, in a broader sense.
Should You Add Chemours To Your Watchlist?
One positive for Chemours is that it is growing EPS. That's nice to see. The fact that EPS is growing is a genuine positive for Chemours, but the pleasant picture gets better than that. Boasting both modest CEO pay and considerable insider ownership, you'd argue this one is worthy of the watchlist, at least. You still need to take note of risks, for example - Chemours has 2 warning signs we think you should be aware of.
Although Chemours certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see insider buying, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對於許多投資者,尤其是那些缺乏經驗的投資者來説,購買有好故事的公司的股票是很常見的,即使這些公司在虧損。有時,這些故事可能會矇蔽投資者的頭腦,導致他們以自己的情緒投資,而不是投資於良好的公司基本面。虧損的公司可能會像海綿一樣吸收資本,因此投資者應該謹慎,不要把錢一筆接一筆地往上扔。
因此,如果這種高風險和高回報的想法不適合,你可能會對盈利的、成長型的公司更感興趣,比如化學公司(紐約證券交易所代碼:CC)。即使這家公司得到了市場的公平估值,投資者也會同意,產生持續的利潤將繼續為化學公司提供為股東增加長期價值的手段。
查看我們對化學的最新分析
中國化工的每股收益正在增長
如果一家公司能夠在足夠長的時間內保持每股收益(EPS)的增長,其股價最終應該會隨之而來。這意味着,大多數成功的長期投資者認為,每股收益的增長是一個真正的積極因素。在三年的時間裏,化學公司設法使每股收益以每年17%的速度增長。這是一個相當不錯的比率,如果公司能夠維持下去的話。
營收增長是一個很好的指標,表明增長是可持續的,再加上高息税前利潤(EBIT)利潤率,這是一家公司在市場上保持競爭優勢的絕佳方式。Chemour股東聽到的消息是,在過去12個月裏,息税前利潤從8.2%增長到15%,收入也呈上升趨勢。在我們的書中,勾選這兩個方框是增長的一個好跡象。
你可以在下面的圖表中看到該公司的收入和收益增長趨勢。要查看更詳細的信息,請點擊圖片。
紐約證券交易所:CC收益和收入歷史2022年9月28日作為投資者,訣竅在於找到符合以下條件的公司要去在未來有好的表現,而不僅僅是在過去。雖然水晶球並不存在,但你可以查看我們對分析師對化學公司未來每股收益100%免費預測的可視化。
Chemour的內部人士是否與所有股東一致?
公司領導人以股東的最佳利益行事是必要的,因此,內部投資總是對市場起到安撫作用。股東們將對內部人士持有價值可觀的化學股份感到高興。具體地説,他們擁有價值4400萬美元的股票。這顯示出大量買入,並可能表明對商業戰略的信心。儘管這隻佔該公司約1.2%的股份,但這筆錢足以表明企業領導人和普通股東之間的關係。
看到內部人士投資於這項業務意義重大,但股東們可能會想,薪酬政策是否符合他們的最佳利益。對CEO薪酬的簡要分析表明,情況的確如此。市值在20億美元至64億美元之間的公司,其首席執行官的總薪酬中值約為690萬美元。
在截至2021年12月的一年裏,Chemour向其首席執行官提供了價值550萬美元的總薪酬。這實際上低於類似規模公司CEO的中位數。CEO薪酬水平不是投資者最重要的衡量標準,但當薪酬適中時,這確實有助於加強CEO與普通股東之間的一致性。在更廣泛的意義上,它也可以是一種誠信文化的標誌。
你應該將化學添加到你的觀察名單中嗎?
化學的一個利好消息是,它的每股收益正在增長。很高興見到你。每股收益增長的事實對化學來説是一個真正的積極因素,但令人高興的是,情況還不止於此。你可能會説,這家公司CEO的薪酬不高,內部人士的所有權也相當可觀,因此至少值得被列入觀察名單。例如,你仍然需要注意風險-化學公司2個警告標誌我們認為你應該意識到。
儘管Chemour看起來確實不錯,但如果內部人士買入股票,它可能會吸引更多的投資者。如果你想看到內幕交易,那麼這本書免費內部人士正在收購的成長型公司名單,可能正是你正在尋找的。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧